Malaria Radical Cure Drug Efficacy Clinical Study

The Defense Health Agency Contracting Activity (DHACA) intends to award a sole source contract to The Research Foundation for The State University of New York (SUNY) for a Malaria Radical Cure Drug Efficacy Clinical Study. The study includes two clinical studies with two phases: one to measure the safety and pharmacokinetics of tafenoquine in healthy adults in the U.S., and another to measure the efficacy of tafenoquine in treating malaria in an endemic area in Thailand. • The contract is for a non-personal services contract to conduct research. • The study will be conducted in conjunction with the Walter Reed Army Institute of Research (WRAIR) and the Armed Forces Research Institute of Medical Sciences (AFRIMS). • Capability statements are due by 08:00 AM EDT on Saturday, 25 April 2026.